Therapeutic Monitoring Systems Inc

Presenter: Stephen Fanjoy, President

Company Profile

Therapeutic Monitoring Systems (TMS) is commercializing CIMVA, a point-of-care clinical decision support software application platform. CIMVA provides new physiologic insight that assists critical care physicians to make more timely and effective treatment decisions, enabling improved patient outcomes and significantly lower the cost of critical care. Our lead application will be submitted for 510(k) regulatory approval in late 2010. The company is garnering interest and support from key clinical opinion leaders in critical care and from leading multinational vital sign monitoring vendors.

Company Strategy

CIMVA will be commercialized as subscription-licensed software targeted for use initially in ICUs in large urban teaching hospitals in the US and Canada. Follow-on market segments include expansion to all in-hospital monitored beds, ambulatory and remote patient monitoring. Our commercialization strategy includes both direct sales to key opinion leader critical care clinician scientists and partnering agreements with vital sign monitoring original equipment manufacturers.

Intellectual Property

Issued and pending international patents, trade secrets, copyright and trademarks.

Programs

CIMVA (continuous, individualized multi-organ variability analysis) is a patented method of measuring clinically significant changes in the degree and character of the variability of a patient's physiological biosignals over time. Compared to the current standard of care, clinical trials have demonstrate that CIMVA enables:
- 24 hours earlier detection of the onset of infection, and
- 71% reduction in incorrect decisions to extubate (remove) patients from mechanical ventilation.
This clinical efficacy is backed by significant financial benefits, including reduced length of stay, annual ROI greater then 10x and payback within one month.

Investors

Private investors in Ottawa, Toronto and San Francisco.

Management Team

Stephen Fanjoy, President
Dr. Andrew Seely, Chief Science Officer
Simon Goulet, Chief Operating Officer

Presenter Bio

Stephen Fanjoy leads the implementation of the TMS strategy in the areas of capitalization, commercialization, business development, marketing and product management. Prior to joining TMS, Stephen has helped lead many software startups to define and successfully execute their business strategy and plans, including sell-side M&A and financings valued at over $60 million. Stephen has over 16 years experience in enterprise software, including senior management roles in product management, marketing, analyst relations, alliances and business development for SHL VISION* Solutions (acquired by Autodesk), Oracle and Watchfire (acquired by IBM). Stephen is a founding member of the Board of Directors of the Ontario Bioscience Industry Organization (OBIO) and a Director of CMC Ontario. Stephen is an honours graduate of the Dalhousie University School of Business and a Certified Management Consultant.

Contact

Therapeutic Monitoring Systems Inc
501 Smyth Road, Box 800
Ottawa
Ontario, Canada
K1H 8L6

ph: 613-255-5617
fx: 613-216-9279

www.therapeuticmonitoring.com
sfanjoy@therapeuticmonitoring.com

April 6-8, 2010